Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 45 | Beijing GoBroad HospitalOTHER | 1 | Jun 11, 2025 |
| clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06485739 | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 20 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jul 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2026source: clinicaltrials